Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Research news A University of Texas at El Paso study has found that people with type 2 diabetes or obesity who used glucagon-like peptide-1 receptor agonists had lower odds of alcohol, opioid, nicotine and cocaine use disorders, although researchers said clinical trials were needed before the drugs could be considered for addiction treatment A study led by researchers at The University of Texas at El Paso, USA, has found that the use of diabetes and weight loss medicines such as Ozempic was associated with a lower risk of alcohol, opioid, nicotine and cocaine use disorders
Pathways involved in obesity AMPK activation reduces eukaryotic translation initiation factor 2 (eIF2) and SREBP-1 levels, reducing adipogenesis (Desjardins and Steinberg 2018
Understanding why these FDA-approved GLP-1 receptor agonists may not work as expected requires examining multiple factorsfrom medication dosing and administration technique to underlying medical conditions and lifestyle behaviors
As your primary care provider, we also look at: Your overall health For example, we note if you have other medical conditions that could affect your ability to lose weight, such as hypothyroidism
You may want to take a pregnancy test
This long-anticipated decision will allow dozens of cases to be consolidated in federal court, which can lead to a faster and more streamlined legal process
